Oscotec said on the 27th that it swung to an operating profit of 52.08329 billion won on a consolidation basis last year. Revenue for the same period rose 193.5% from a year earlier to 99.83866 billion won.
The company cited as the backdrop for the results the milestone payments received after the combination therapy of the Non-small cell lung cancer (NSCLC) treatment "Leclaza (ingredient name Lazertinib)" and Janssen's Rybrevant (Amivantamab) began sales in Japan in March and China in July last year, as well as royalties tied to increased prescriptions at home and abroad. Oscotec originally developed Lazertinib and licensed it out to Yuhan.
An upfront payment received upon licensing out the new Alzheimer's drug candidate targeting tau protein, "Adel-Y01 (ADEL -Y01)," to France's Sanofi also propelled revenue.
Oscotec plans to build a "Dual-Hub model" with its U.S. subsidiary Genosco, maintaining each side's expertise while maximizing cost and operational efficiency through integrated management.
Meanwhile, Oscotec last month introduced as its mid- to long-term R&D core strategy an "anti-resistance anticancer drug" that fundamentally blocks resistance and a "DAC (antibody–degrader conjugate) platform" with enhanced safety.
The company is conducting research and development to strengthen the durability and efficiency of cancer treatment through anti-resistance anticancer drugs, while targeting cancer types with limited treatment options to preempt scalable market opportunities.
Chief Executive Yun Tae-young of Oscotec said, "We are seeking external partnering so that it can be born as a patient-customized innovative new drug without injecting additional internal expense."